2024-04-022024-04-022013-03Demirkaya, M. (2013). “Randomized comparison of piperacillin-tazobactam plus amikacin versus cefoperazone-sulbactam plus amikacin for management of febrile neutropenia in children with lymphoma and solid tumors”. Pediatric Hematology and Oncology, 30(2), 141-148.0888-0018https://doi.org/10.3109/08880018.2012.756565https://www.tandfonline.com/doi/full/10.3109/08880018.2012.756565https://hdl.handle.net/11452/40904The objective of this study was to compare the effectiveness of piperacillin-tazobactam(PIP/TAZO) plus amikacin (AMK) (PIP/TAZO+AMK) versus cefoperazone-sulbactam (CS) plus AMK (CS+AMK) for the treatment of febrile neutropenia (FN) in children with cancer. The study was designed prospectively and randomized in 0- to 18-year-old children with lymphoma or solid tumor who were hospitalized with FN diagnosis. Consecutively randomized patients received either PIP/TAZO 360 mg/kg/day in 4 doses plus AMK 15 mg/kg/day in 3 doses or CS 100 mg/kg/day in 3 doses plus AMK 15 mg/kg/day in 3 doses intravenously. Treatment modification was defined as any change in the initial empirical antibiotic therapy. A total of 116 FN episodes were managed in 46 patients (26 boys and 20 girls) with a median age of 6.5 years (range .8-17.0) during the study period. Success rates without modification of therapy were 47.5% and 52.6% in PIP/TAZO+AMK group and CS+AMK group, respectively (P>.05). No statistical difference was found between treatment groups in terms of durations of neutropenia, fever, and hospitalization. The overall success rate in all groups was 97.4%. No major side effect was observed in either group during the course of the study. Our study is the first to compare the effectiveness of PIP/TAZO+AMK and CS+AMK therapies. Both combinations were effective and safe as empirical therapy for febrile neutropenic patients.eninfo:eu-repo/semantics/closedAccessOncologyHematologyPediatricsAmikacinCefoperazone-sulbactamChildhood cancerFebrile neutropeniaPiperacillin-tazobactamPediatric cancer-paitientsEmpirical-treatmentMonotherapyCefepimeTherapyFeverImipenemMetaanalysisNetilmicinInfectionAdolescentAmikacinAnti-bacterial agentsCefoperazoneChildChild, preschoolDrug therapy, combinationFemaleHumansInfantLymphoma, non-hodgkinMaleNeutropeniaPenicillanic acidPiperacillinProspective studiesSulbactamArticle0003165674000092-s2.0-8487390057814114830223301757OncologyHematologyPediatricsCancer; Coagulase Negative Staphylococci; Piperacillin Plus TazobactamAmikacinPiperacillinSulperazonAdolescentAdultArticleChildChild hospitalizationClinical articleComparative effectivenessControlled studyDisease durationDrug efficacyFebrile neutropeniaFemaleHumanInfantMaleNewbornPreschool childProspective studyRandomized controlled trialSchool childTreatment outcome;Unspecified side effect